Anagrelide Retard in Essential Thrombocythemia

NCT02076815 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Thrombocythemia

Interventions

DRUG: Anagrelide retard
DRUG: Thromboreductin

Sponsor

AOP Orphan Pharmaceuticals AG